Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27243730 | 0.91 | KDM4E (0.41) | ATAD2 | |
| SCHEMBL11147060 | 0.80 | ATAD2 (0.44) | ATAD2 | |
| SCHEMBL10726378 | 0.77 | MEN1 (0.43) | ATAD2 | |
| SCHEMBL4353311 | 0.76 | DPYD (0.50) | ATAD2 | |
| SCHEMBL27433771 | 0.73 | DPYD (0.38) | — | |
| SCHEMBL29767278 | 0.73 | HCAR2 (0.50) | ATAD2 | |
| SCHEMBL156784 | 0.73 | ATAD2 (0.48) | ATAD2 | |
| SCHEMBL1546531 | 0.72 | GAA (0.40) | — | |
| SCHEMBL27589203 | 0.71 | GAA (0.39) | — | |
| SCHEMBL27663548 | 0.71 | LMNA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777024-B2 | Process for preparing a pentopyranosyl nucleic acid conjugate | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20090221793-A1 | PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE | SANOFI-AVENTIS S.A. (FR) | 2009-09-03 | — | — | US | disclosed |
| US-7501506-B2 | Pentopyranosyl nucleic acid conjugates | NANOGEN RECOGNOMICS GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221793-A1 | PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE | RNGTT, NT5C3B, FUT6 | ATAD2 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.